Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
310 participants
OBSERVATIONAL
2020-06-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. Methods:
* Survey on health risk awareness and lifestyle for COVID-19
* Blood and urine tests for exposure to environmentally hazardous chemicals
* Collection of hospital clinical data utilization for indicators related to chronic kidney disease
3. Clinical endpoints:
* Verification of differences in health risk perception level and lifestyle changes
* Verification of changes in lifestyle changes and exposure to environmentally hazardous chemicals
* Verification of changes in indicators related to kidney disease according to changes in exposure to environmentally hazardous chemicals
4. Statistical methods: chi-square test, independent mean comparison t-test, ANOVA test, regression analysis
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Hypothesis and Purpose
* Differences in risk perception for disease after the COVID-19 pandemic can explain the degree of change in lifestyle.
* The changed lifestyle will lead to reduced exposure to environmentally hazardous substances.
* Reduction of exposure to environmentally harmful substances will reduce the level of exposure to harmful substances related to kidney disease, which will lead to changes in the prevalence of kidney disease and indicators related to kidney disease.
* After the COVID-19 pandemic, it is verified whether the exposure level of environmentally hazardous chemicals decreases due to changes in the way of life and differences in perception of the risk of infectious diseases, and confirms which indicators related to chronic kidney disease change accordingly. Identify the role.
3. Methods (1) During the COVID-19 pandemic
* Acquisition of consent (using explanations and posters) by explaining the research purpose and method
* Survey on changes in awareness of diseases and changes in hygiene activities since the COVID-19 pandemic compared to before
* Measurement of the concentration of environmentally hazardous substances through the acquisition of blood (serum, residual samples after blood tests for treatment) and urine samples that are normally performed in the office (3 months cycle, 4 times)
* Acquisition of clinical information related to kidney disease (2) Recovery period of the COVID-19 pandemic
* Survey on changes in awareness of diseases and hygiene activities that have changed since the end of the COVID-19 outbreak
* Measurement of the concentration of environmentally harmful substances by obtaining blood (serum, residual sample after blood test for medical treatment) and urine sample (once after 6 months of termination)
* Acquisition of clinical information related to kidney disease (3) Investigation variable
a) Survey
* Demographic information
* Anthropometric information
* Risk perception for the COVID-19
* Individual behavior associated with hygiene
* Social distancing pattern b) Chemical material in human sample (blood, urine)
* Phthalate metabolite
* Paraben metabolite
* Benzophenone
* Triclosan and triclocarban
* Bisphenols
* Phosphate metabolites
* Organochlorine pesticides
* Polychlorinated biphenyls c) Clinical information including estimated glomerular filtration rate, urine protein/creatinine ratio
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* who have been treated twice or more with chronic kidney disease as their main diagnosis in an outpatient department of kidney medicine for more than 3 months
Exclusion Criteria
* Patients who are likely to significantly change their lifestyle and exposure levels of environmentally hazardous chemicals due to the rapid progression of the disease itself, accompanied by the following chronic diseases (malignant tumors, dementia, immunosuppressants Use, stroke within 1 year, cerebral hemorrhage, myocardial infarction)
* Other patients who have difficulty in general communication or who are unable to carry out their daily life on their own
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jung Pyo Lee
Principal Investigator, M.D., Ph.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jung Pyo Lee, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
SMG-SNU Boramae Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Boramae Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jeonghwan Lee, Prof.
Role: primary
Yaerim Kim, Prof.
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Street ME, Angelini S, Bernasconi S, Burgio E, Cassio A, Catellani C, Cirillo F, Deodati A, Fabbrizi E, Fanos V, Gargano G, Grossi E, Iughetti L, Lazzeroni P, Mantovani A, Migliore L, Palanza P, Panzica G, Papini AM, Parmigiani S, Predieri B, Sartori C, Tridenti G, Amarri S. Current Knowledge on Endocrine Disrupting Chemicals (EDCs) from Animal Biology to Humans, from Pregnancy to Adulthood: Highlights from a National Italian Meeting. Int J Mol Sci. 2018 Jun 2;19(6):1647. doi: 10.3390/ijms19061647.
Grandjean P, Bellanger M. Calculation of the disease burden associated with environmental chemical exposures: application of toxicological information in health economic estimation. Environ Health. 2017 Dec 5;16(1):123. doi: 10.1186/s12940-017-0340-3.
Mascarelli A. Environment: toxic effects. Nature. 2012 Mar 15;483(7389):363-5. doi: 10.1038/nj7389-363a. No abstract available.
Watts N, Amann M, Ayeb-Karlsson S, Belesova K, Bouley T, Boykoff M, Byass P, Cai W, Campbell-Lendrum D, Chambers J, Cox PM, Daly M, Dasandi N, Davies M, Depledge M, Depoux A, Dominguez-Salas P, Drummond P, Ekins P, Flahault A, Frumkin H, Georgeson L, Ghanei M, Grace D, Graham H, Grojsman R, Haines A, Hamilton I, Hartinger S, Johnson A, Kelman I, Kiesewetter G, Kniveton D, Liang L, Lott M, Lowe R, Mace G, Odhiambo Sewe M, Maslin M, Mikhaylov S, Milner J, Latifi AM, Moradi-Lakeh M, Morrissey K, Murray K, Neville T, Nilsson M, Oreszczyn T, Owfi F, Pencheon D, Pye S, Rabbaniha M, Robinson E, Rocklov J, Schutte S, Shumake-Guillemot J, Steinbach R, Tabatabaei M, Wheeler N, Wilkinson P, Gong P, Montgomery H, Costello A. The Lancet Countdown on health and climate change: from 25 years of inaction to a global transformation for public health. Lancet. 2018 Feb 10;391(10120):581-630. doi: 10.1016/S0140-6736(17)32464-9. Epub 2017 Oct 30. No abstract available.
Obrador GT, Schultheiss UT, Kretzler M, Langham RG, Nangaku M, Pecoits-Filho R, Pollock C, Rossert J, Correa-Rotter R, Stenvinkel P, Walker R, Yang CW, Fox CS, Kottgen A. Genetic and environmental risk factors for chronic kidney disease. Kidney Int Suppl (2011). 2017 Oct;7(2):88-106. doi: 10.1016/j.kisu.2017.07.004. Epub 2017 Sep 20.
Song JY, Yun JG, Noh JY, Cheong HJ, Kim WJ. Covid-19 in South Korea - Challenges of Subclinical Manifestations. N Engl J Med. 2020 May 7;382(19):1858-1859. doi: 10.1056/NEJMc2001801. Epub 2020 Apr 6. No abstract available.
Kang H, Kim S, Lee G, Lee I, Lee JP, Lee J, Park H, Moon HB, Park J, Kim S, Choi G, Choi K. Urinary metabolites of dibutyl phthalate and benzophenone-3 are potential chemical risk factors of chronic kidney function markers among healthy women. Environ Int. 2019 Mar;124:354-360. doi: 10.1016/j.envint.2019.01.028. Epub 2019 Jan 17.
Kang H, Lee J, Lee JP, Choi K. Urinary metabolites of organophosphate esters (OPEs) are associated with chronic kidney disease in the general US population, NHANES 2013-2014. Environ Int. 2019 Oct;131:105034. doi: 10.1016/j.envint.2019.105034. Epub 2019 Jul 30.
Lee J, Oh S, Kang H, Kim S, Lee G, Li L, Kim CT, An JN, Oh YK, Lim CS, Kim DK, Kim YS, Choi K, Lee JP. Environment-Wide Association Study of CKD. Clin J Am Soc Nephrol. 2020 Jun 8;15(6):766-775. doi: 10.2215/CJN.06780619. Epub 2020 May 22.
Kang MW, Kim Y, Lee I, Park H, Park JY, An JN, Yoo KD, Kim YC, Park NY, Kho Y, Choi K, Lee JP, Lee J. Longitudinal behavioral changes and factors related to reinforced risk aversion behavior among patients with chronic kidney disease during the COVID-19 pandemic. Sci Rep. 2022 Sep 22;12(1):15780. doi: 10.1038/s41598-022-19787-0.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SKETCH
Identifier Type: -
Identifier Source: org_study_id